Laurence de Schoulepnikoff
Chief Operating Officer chez OSE IMMUNOTHERAPEUTICS
Profil
Laurence de Schoulepnikoff is currently the Chief Executive Officer at Tridek-One Therapeutics SAS and the Director at Swiss Healthcare Licensing Group.
Ms. de Schoulepnikoff's most recent position is the Chief Operating & Business Officer at OSE Immunotherapeutics SA, which started in 2021.
Ms. de Schoulepnikoff previously held the position of Chief Operating & Business Officer at Amal Therapeutics SA. Ms. de Schoulepnikoff is a graduate of École Polytechnique Fédérale de Lausanne.
Postes actifs de Laurence de Schoulepnikoff
| Sociétés | Poste | Début |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Chief Operating Officer | 16/01/2022 |
| Swiss Healthcare Licensing Group | Director/Board Member | - |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Chief Executive Officer | - |
Anciens postes connus de Laurence de Schoulepnikoff
| Sociétés | Poste | Fin |
|---|---|---|
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Chief Operating Officer | - |
Formation de Laurence de Schoulepnikoff
| École Polytechnique Fédérale de Lausanne | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Entreprise privées | 3 |
|---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
| Swiss Healthcare Licensing Group | |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Commercial Services |
